Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Dx Sales Increase 3 Percent in Q1

NEW YORK (GenomeWeb News) – Roche reported today that first-quarter revenues for its diagnostics division, which includes its molecular diagnostics and applied science businesses, rose 3 percent to CHF2.36 billion ($2.06 billion) year over year.

The Swiss drugs and diagnostics giant said that its molecular diagnostics business brought in revenues of CHF294 million for the quarter with growth driven by automated real-time PCR platforms and blood-screening products.

Its applied science business generated revenues of CHF196 million for the quarter led by the sale of DNA sequencing products and microarrays, which both posted high double-digit growth, said Roche. The firm's tissue diagnostics business had Q1 sales of CHF106 million, driven by last year's $3.4 billion acquisition of Ventana Medical Systems.

Overall, the Roche Group had first-quarter revenues of CHF11.58 billion, up 7 percent year over year. That growth was driven largely by its pharmaceutical division, which posted 8 percent growth to CHF9.21 billion.

"Sales in both divisions continued to grow significantly faster than their respective markets," Roche CEO Severin Schwan said in a statement. "We are therefore confident that we can achieve our full-year targets."

Roche said that it will update its full-year outlook when it releases its half-year results. Earlier this year, the firm said that it expects mid-single digit sales growth for 2009, but that was before it inked the definitive agreement to acquire the remaining interest in Genentech.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more